Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

143 results about "A baumannii" patented technology

Primer probe combination and kit for combined inspection of 15 kinds of respiratory tract infection pathogens

The invention provides a pathogen inspection reagent, and concretely discloses a primer probe combination and a kit for combined inspection of 15 kinds of respiratory tract infection pathogens. By aiming at specific target sequences of the gene sequence conserved region of klebsiella pneumoniae, haemophilus influenzae, streptococcus pyogenes, staphylococcus aureus, escherichia coli, chlamydia pneumoniae, mycobacterium tuberculosis, stenotrophomonas maltophilia, baumanii, mycoplasma pneumoniae, enterococcus faecalis, ligionella pneumohpillia, streptococcus pneumoniae, bacillus pyocyaneus and mycobacterium abscessus, primers and probes which do not have mutual crossed reaction are designed, so that the problem that detection probes of different pathogens can easily generate mutual influenceor interference is solved; the combination and matching of different primers and probes are ensured; the goal of simultaneously performing efficient specific inspection at the same temperature can also be achieved.
Owner:西安九安生物技术有限公司

Primer and probe combination and kit for detecting human pathogenic bacteria

The invention relates to the technical field of medical detection, and in particular, relates to a primer and probe combination and a kit for detecting human pathogenic bacteria. The kit comprises theprimer and probe combination for detecting pseudomonas aeruginosa, escherichia coli, klebsiella pneumoniae, staphylococcus epidermidis, staphylococcus aureus, enterococcus faecium, human staphylococcus and acinetobacter baumannii. According to the kit, the primer and probe combination is adopted, multiple digital PCR is combined, the pathogenic bacteria types and the target nucleic acid copy number in the detection range can be rapidly and accurately identified, the detection method has high sensitivity, and positive detection of low-copy nucleic acid fragments of pathogenic bacteria is guaranteed; meanwhile, the variety of the pathogenic bacteria or the change of the copy number of the target nucleic acid fragment in the body of a pathogenic bacteria infected patient can be dynamically monitored, the treatment effect is assisted and evaluated in time, and reference is provided for optimization of a doctor clinical scheme.
Owner:PILOT GENE TECH HANGZHOU CO LTD

Norwogonin and application thereof to preparation of medicines for treating acinetobacter baumannii infection

The invention relates to an application of norwogonin to preparation of medicines for treating acinetobacter baumannii infection and complications caused by the acinetobacter baumannii infection. Acinetobacter baumannii is resistant to a variety of antibiotics and the norwogonin can inhibit growth of the acinetobacter baumannii with multidrug resistance; an in-vitro drug susceptibility test proves that during independent use of the norwogonin, the minimum inhibitory concentration of the norwogonin is half of the minimum inhibitory concentration of the conventional therapeutic medicine imipenem, which means that the inhibitory effect of the norwogonin is better; combination of the norwogonin and the imipenem can achieve a synergistic effect on the growth of the acinetobacter baumannii with the multidrug resistance; and an acute toxicity test on a mouse proves that the using safety of the norwogonin is high, which means that the norwogonin has a good medicinal prospect.
Owner:程新明

Multiple PCR detection kit and method for identifying susceptible bacteria species for intracranial post-operation

The invention aims to provide a multiple PCR detection kit and a method for identifying susceptible bacteria species for intracranial post-operation to eliminate endogenous nucleic acid contamination. The detected bacteria species are the following common bacteria: staphylococcus aureus, enterococcus faecalis, streptococcus pneumoniae, escherichia coli, bacillus pyocyaneus, klebsiella pneumoniae and acinetobacter baumannii. Meanwhile, the invention provides the method to eliminate the endogenous nucleic acid contamination in a raw material of a PCR system and exclude a false positive experimental result of a PCR caused by the endogenous nucleic acid contamination. The detecting method using the kit has the advantages of that the operation is simple and fast, the detection cost is lowered, the detection result is accurate, and the false positive result is reduced. A negative control and a positive control are added in the amplification step, so that the judgment of false positive and false negative is effectively improved, and the detection accuracy is higher.
Owner:江苏睿玻生物科技有限公司

Application of blue light activated (S)-blebbistatin molecules to killing of drug-resistant acinetobacter baumannii, and method for killing drug-resistant acinetobacter baumannii through blue light activated (S)-blebbistatin molecules

The invention relates to application of blue light activated (S)-blebbistatin molecules to killing of drug-resistant acinetobacter baumannii, and a method for killing the drug-resistant acinetobacterbaumannii through the blue light activated (S)-blebbistatin molecules. (S)-blebbistatin molecules are used for cooperating with blue light, and the (S)-blebbistatin molecules generate strong-oxidativehydroxyl radicals (.OH) under blue light irradiation, and can kill the drug-resistant acinetobacter baumannii. (S)-blebbistatin and a bacterial solution are mixed evenly to be irradiated under the blue light and then smeared or dotted on the surface of a flat plate for a period of time, and then it can be observed that the clinical drug-resistant acinetobacter baumannii is killed. The sterilizingefficiency is improved with increasing of the time, and the inducible drug resistance risk is avoided under the condition without light. The application and the method are not limited by bacterial drug resistance, and provide solid and powerful technical support for treatment of the clinical multiple-drug-resistant acinetobacter baumannii.
Owner:THE THIRD PEOPLES HOSPITAL OF SHENZHEN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products